Description:
This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the
treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
Currently enrolling melanoma patients in combination with nivolumab, only.
Title
- Brief Title: PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)
- Official Title: A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Clinical Trial IDs
- ORG STUDY ID:
KCP-9274-901
- NCT ID:
NCT02702492
Conditions
Interventions
Drug | Synonyms | Arms |
---|
KPT-9274 | | KPT-9274 |
Niacin ER | | KPT-9274 & Niacin Extended Release (ER) |
Nivolumab | Opdivo® | KPT-9274 + Nivolumab |
Purpose
This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the
treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
Currently enrolling melanoma patients in combination with nivolumab, only.
Detailed Description
This is a first-in-human, multi-center, open-label clinical study with separate Dose
Escalation and Expansion Phases to assess preliminary safety, tolerability, and efficacy of
KPT-9274, a dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies
(including sarcoma, colon, lung, melanoma, etc.) or NHL for which all standard therapeutic
options considered useful by the investigator have been exhausted.
Trial Arms
Name | Type | Description | Interventions |
---|
KPT-9274 | Experimental | Part A: [CLOSED TO ENROLLMENT]
Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle. | |
KPT-9274 & Niacin Extended Release (ER) | Experimental | Part B:[CLOSED TO ENROLLMENT]
500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle. | |
KPT-9274 + Nivolumab | Experimental | Part C:
Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.
Nivolumab 480 mg IV administered Day 1 during each 28 day cycle. | |
Eligibility Criteria
Inclusion Criteria:
Participants must meet all of the following inclusion criteria to be eligible to enroll in
the Part C of this study.
1. Should have unresectable advanced, recurrent or metastatic melanoma and must have
objective and measurable melanoma by RECIST 1.1 after disease progression on a prior
anti-PD-1 or anti-PD-L1 therapy.
2. ECOG performance status of ≤ 2.
3. Life expectancy of ≥ 3 months.
4. Adequate hepatic function:
- Total bilirubin < 1.5 times the ULN (except participants with Gilbert's syndrome
[hereditary indirect hyperbilirubinemia] who must have a total bilirubin of ≤ 3
times ULN),
- AST and ALT ≤ 2.5 times ULN (except participants with known liver involvement of
their advanced solid malignancy who must have an AST and ALT ≤ 5.0 times ULN).
5. Adequate renal function:
- Estimated creatinine clearance of ≥ 60 mL/min, calculated using the formula of
Cockroft and Gault (140-Age) Mass (kg)/(72 creatinine mg/dL); multiply by 0.85 if
female.
6. Adequate hematopoietic function:
- Total WBC count ≥ 1500/mm³, ANC ≥ 1000/mm³, Hb ≥ 10.0 g/dL, platelet count ≥
100,000/mm³
Exclusion Criteria:
Participants meeting any of the following exclusion criteria are not eligible to enroll in
this study.
1. ≤ 2 weeks since the last prior therapeutic regimen for melanoma. Palliative steroids
for disease related symptoms < 7 days prior to C1D1, unless physiologic doses of
steroids are used.
2. Have not recovered or stabilized (Gr 1 or to their baseline for non-hematologic
toxicities, ≤ Gr 2 or to their baseline for hematologic toxicities) from toxicities
related to their previous treatment except for alopecia.
3. Untreated CNS disease or leptomeningeal involvement are excluded. Participants without
active brain or leptomeningeal metastases after prior treatment with local therapies
are eligible provided that the treatment had been done ≥ 2 weeks prior to enrollment.
4. Active infection with completion of therapeutic antibiotics, antivirals, or
antifungals within one week prior to C1D1. Prophylactic antibiotics, antivirals or
antifungals are permitted.
5. Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting
or diarrhea that could interfere with the absorption of KPT-9274.
6. Active peptic ulcer disease or other active gastrointestinal bleeds.
7. Requiring treatment with corticosteroids at doses higher than substitute therapy (> 10
mg prednisone), are unstable with substitute hormonal therapy, or are deemed to be
likely to re-occur by the treating physician when administered nivolumab.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Maximum tolerated dose (MTD) for KPT-9274 administered alone and with co-administration of niacin ER (extended release) (vitamin B3/nicotinic acid) |
Time Frame: | Approximately 4 weeks |
Safety Issue: | |
Description: | Parts A & B: MTD will be based on the assessment of dose limiting toxicities (DLTs) during the first cycle of therapy and will be defined as the highest dose at which ≤1 participant out of 6 (or 0 out of 3) experiences DLTs within Cycle 1. |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Terminated |
Lead Sponsor: | Karyopharm Therapeutics Inc |
Trial Keywords
- PAK4
- KPT-9274
- Karyopharm
- NHL
- Solid Tumors
- NAMPT
- Melanoma
Last Updated
June 25, 2021